Thus, although scarce, concomitant genetic alterations appear to be another important determinant of tumor biology and patient outcome in ALK-driven NSCLC, beside the oncogenic driver, i.e. the ALK fusion itself. Here, ALK is linked to non-small cell lung carcinoma.